Jpmorgan Chase & CO Evolus, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Evolus, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 213,954 shares of EOLS stock, worth $3.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

213,954

Previous 247,656 13.61%

Holding current value

$3.51 Million

Previous $3.47 Million 33.05%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$10.45 - $13.76 $352,185 - $463,739	-33,702 Reduced 13.61%	213,954 $2.32 Million
Q1 2024 May 10, 2024	BUY	$9.99 - $14.91 $2.09 Million - $3.12 Million	209,183 Added 543.71%	247,656 $3.47 Million
Q4 2023 Feb 12, 2024	SELL	$7.6 - $10.53 $702,445 - $973,256	-92,427 Reduced 70.61%	38,473 $405,000
Q3 2023 Nov 14, 2023	BUY	$7.15 - $10.2 $691,626 - $986,656	96,731 Added 283.1%	130,900 $1.2 Million
Q2 2023 Aug 11, 2023	BUY	$7.23 - $10.52 $31,602 - $45,982	4,371 Added 14.67%	34,169 $248,000
Q1 2023 May 18, 2023	BUY	$7.81 - $11.05 $211,869 - $299,764	27,128 Added 1016.03%	29,798 $252,000
Q1 2023 May 11, 2023	SELL	$7.81 - $11.05 $841,886 - $1.19 Million	-107,796 Reduced 97.58%	2,670 $22,000
Q4 2022 Feb 13, 2023	BUY	$6.52 - $8.95 $567,781 - $779,392	87,083 Added 372.42%	110,466 $829,000
Q3 2022 Nov 14, 2022	BUY	$7.76 - $13.72 $14,433 - $25,519	1,860 Added 8.64%	23,383 $188,000
Q2 2022 Aug 11, 2022	SELL	$10.22 - $13.94 $8,063 - $10,998	-789 Reduced 3.54%	21,523 $250,000
Q1 2022 May 11, 2022	BUY	$5.22 - $11.78 $27,138 - $61,244	5,199 Added 30.38%	22,312 $251,000
Q4 2021 Feb 10, 2022	BUY	$5.37 - $8.38 $26,307 - $41,053	4,899 Added 40.11%	17,113 $111,000
Q3 2021 Nov 12, 2021	BUY	$7.36 - $13.67 $89,895 - $166,965	12,214 New	12,214 $94,000

Others Institutions Holding EOLS

# of Institutions

166

Shares Held

49.4M

Call Options Held

453K

Put Options Held

14K

View Full List

About Evolus, Inc.

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $921M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

More about EOLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Evolus, Inc. Transaction History